Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab
Authors
Felip, E.Doger, B.
Majem, M.
Carcereny, E.
Krebs, Matthew G
Peguero, J. A.
Roxburgh, P.
Forster, M.
Bajaj, P.
Clay, T. D.
Triebel, F.
Affiliation
Vall d’Hebron Institute of Oncology (VHIO), Barcelona, SpainIssue Date
2020